Immune checkpoint inhibitors (ICIs) have dramatically improved patient outcomes in a
variety of tumor types, but with variable efficacy. Recent research has suggested that …

Background This study aimed to assess the effect of antibiotics on the clinical outcomes of
patients with solid cancers undergoing treatment with immune checkpoint inhibitors (ICIs) …

Objectives Observational and experimental studies suggest that the use of antibiotics close
to administration of immune checkpoint inhibitors (ICI) can have a negative effect on tumour …

Abstract Background Immune checkpoint inhibitors (ICIs) are essential for treatment of
various malignancies, including non–small-cell lung cancer (NSCLC). Recently, several …

Purpose Pre-clinical and early clinical data suggests the microbiome plays an important role
in oncogenesis and influences response to immune checkpoint blockade (ICB). The …

Purpose In this study, we test the hypothesis that the use of ATB reduces the efficacy of PD
(L) 1-targeting mAb. Methods We included patients with locally advanced, inoperable or …

Background With the advent of immunotherapy, substantial progress has been made in
improving outcomes for patients with advanced cancer. However, not all patients benefit …

Introduction Gut dysbiosis may reduce immune checkpoint inhibitor (ICI) efficacy. Antibiotics
and proton pump inhibitors (PPIs) are commonly used drugs causing gut dysbiosis. There is …

We carried out a retrospective cohort study on patients with advanced cancer treated with
immune checkpoint inhibitors (ICIs) to determine whether antibiotics affect treatment …

Background Some concomitant medications including antibiotics (ATB) have been
reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in …